{"id":"mk0966-rofecoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Myocardial infarction"},{"rate":null,"effect":"Stroke"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a selective COX-2 inhibitor, rofecoxib blocks the COX-2 enzyme preferentially over COX-1, thereby reducing prostaglandin E2 and other inflammatory mediators. This mechanism provides anti-inflammatory and analgesic effects with a theoretical reduction in gastrointestinal toxicity compared to non-selective NSAIDs. However, selective COX-2 inhibition was later associated with increased cardiovascular thrombotic risk.","oneSentence":"Rofecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:40.664Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoarthritis"},{"name":"Rheumatoid arthritis"},{"name":"Acute pain"},{"name":"Dysmenorrhea"}]},"trialDetails":[{"nctId":"NCT00140894","phase":"PHASE4","title":"A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-08-06","conditions":"Adenomatous Polyposis Coli","enrollment":62},{"nctId":"NCT00038389","phase":"PHASE1","title":"Study of Vioxx and Radiation Therapy for Brainstem Glioma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-10","conditions":"Glioma, Brain Neoplasms","enrollment":8},{"nctId":"NCT00157872","phase":"PHASE4","title":"A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-01-07","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT00140920","phase":"PHASE4","title":"A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-05-25","conditions":"Pain","enrollment":11},{"nctId":"NCT00282386","phase":"PHASE3","title":"A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-12-23","conditions":"Colorectal Adenoma","enrollment":2586},{"nctId":"NCT00092352","phase":"PHASE3","title":"A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-04-29","conditions":"Osteoarthritis","enrollment":395},{"nctId":"NCT00092378","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-09-01","conditions":"Postoperative Pain","enrollment":251},{"nctId":"NCT00092339","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-08-01","conditions":"Postoperative Pain","enrollment":125},{"nctId":"NCT00060476","phase":"PHASE3","title":"Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-01-08","conditions":"Prostate Cancer","enrollment":15000},{"nctId":"NCT00092365","phase":"PHASE3","title":"A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-04-01","conditions":"Osteoarthritis","enrollment":413},{"nctId":"NCT00390260","phase":"PHASE3","title":"Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-02","conditions":"Pain, Postoperative Arthroscopy","enrollment":420},{"nctId":"NCT00092326","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06","conditions":"Postoperative Pain","enrollment":269},{"nctId":"NCT00092313","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06","conditions":"Postoperative Pain","enrollment":271},{"nctId":"NCT00092300","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-05","conditions":"Postoperative Pain","enrollment":450},{"nctId":"NCT01762891","phase":"NA","title":"CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen","status":"COMPLETED","sponsor":"Hospital Universitario Pedro Ernesto","startDate":"2003-03","conditions":"Antiphospholipid Antibody Syndrome","enrollment":22},{"nctId":"NCT00568295","phase":"PHASE3","title":"A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"1999-10","conditions":"Osteoarthritis of the Knee","enrollment":403},{"nctId":"NCT00637949","phase":"PHASE3","title":"Safety of Lumiracoxib in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2000-12","conditions":"Osteoarthritis","enrollment":309},{"nctId":"NCT00140933","phase":"PHASE3","title":"A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-04","conditions":"Pain","enrollment":274},{"nctId":"NCT00165048","phase":"PHASE3","title":"Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2004-10","conditions":"Cancer of Stomach","enrollment":206},{"nctId":"NCT00164892","phase":"PHASE3","title":"Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2004-10","conditions":"Cancer of Stomach","enrollment":214}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MK0966; rofecoxib","genericName":"MK0966; rofecoxib","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK0966 is a small molecule that inhibits the enzyme prostaglandin G/H synthase 2, also known as cyclooxygenase-2. It is classified as a cyclooxygenase-2 inhibitor and has been studied in various clinical trials for conditions such as stomach cancer, postoperative pain, and colorectal adenoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}